<DOC>
	<DOCNO>NCT00005065</DOCNO>
	<brief_summary>Phase I trial study effectiveness combine carboplatin paclitaxel , radiation therapy gadolinium texaphyrin , surgery treating patient stage IIIA non-small cell lung cancer . Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Radiation therapy use high-energy x-rays damage tumor cell . Drugs gadolinium texaphyrin may make tumor cell sensitive radiation therapy . Combining chemotherapy , radiation therapy , surgery may kill tumor cell .</brief_summary>
	<brief_title>Chemotherapy , Radiation Therapy , Surgery Treating Patients With Stage IIIA Non-small Cell Lung Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine compare frequency grade toxicity use gadolinium texaphyrin radiosensitizer two dose level preoperative radiotherapy patient stage IIIA non-small cell lung cancer . II . Measure tumor , involve lymph node , normal lung concentration gadolinium compare image pixel intensity obtain 1.5 Tesla MRI patient population give regimen . OUTLINE : This dose escalation study gadolinium texaphyrin ( Gd-Tex ) . Patients receive paclitaxel IV 3 hour follow carboplatin IV 1-2 hour every 3 week 3 course . Three week completion induction chemotherapy , patient receive Gd-Tex IV 30 minute twice weekly 10 dos preoperative radiotherapy . Radiotherapy administer daily 5 day week 5 week . Approximately 3.5 week completion preoperative radiotherapy , patient undergo complete surgical resection . Three hour prior surgery , patient receive eleventh dose Gd-Tex develop grade 3 4 toxicity tenth dose . Patients also receive MRI without contrast prior surgery . If tumor find unresectable , patient may receive additional radiation and/or chemotherapy . Cohorts 3-6 patient receive escalate dos Gd-Tex maximum tolerate dose ( MTD ) determine . The MTD define dose precede 2 3 2 6 patient experience dose limit toxicity . Patients follow 1 month every 4 month 5 year .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Motexafin gadolinium</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Histologically confirm nonsmall cell carcinoma lung Surgical staging mediastinoscopy anterior thoracotomy require T1T3 , N2 , M0 Must appear resectable Performance status Karnofsky 70100 % WBC least 3,000/mm^3 Absolute neutrophil count least 1,500/mm^3 Platelet count least 100,000/mm^3 Bilirubin normal AST great 2.5 time upper limit normal Creatinine great 2 mg/dL Creatinine clearance least 60 mL/min No symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia FEV great 0.8 L Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Weight loss great 10 % total body weight within past 3 month No evidence neuropathy No history allergy platinum compound , paclitaxel , porphyrin , antiemetic appropriate administration conjunction protocol chemotherapy No concurrent uncontrolled illness ( e.g. , active infection ) No medical contraindication MRI ( e.g. , pacemaker aneurysm clip ) No G6PD deficiency No known history porphyria At least 4 week since prior chemotherapy ( 6 week nitrosoureas ) recover No prior chest radiotherapy area tumor/nodes No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2013</verification_date>
</DOC>